NCT01753414进行中（未招募）2 期
POSTILV: A RANDOMIZED PHASE II TRIAL IN PATIENTS WITH OPERABLE STAGE I NON-SMALL CELL LUNG CANCER: RADICAL RESECTION VERSUS ABLATIVE STEREOTACTIC RADIOTHERAPY - This is a Limited Participation Study.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 44
- 试验地点
- 7
- 主要终点
- Percentage of Participants Alive Without Local-regional Failure at Two Years (Local-regional Tumor Control)
研究概览
简要总结
Rationale: Surgery remains the standard of care for stage 1 (T1-2a N0)non-small cell lung cancer. Stereotactic body radiation therapy is a newer radiation treatment that gives fewer but higher and possibly more effective doses of radiation than standard radiation. This technique may be able to send x-rays directly to the tumor and cause less damage to normal tissue. It is not yet known whether stereotactic body radiation therapy is more effective than surgery in treating non-small cell lung cancer.
Purpose: The primary aim of this randomized phase II trial is to determine if the efficacy of SBRT is comparable to that of standard surgical interventions for patients with T1N0 non-small cell lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically (histologically or cytologically) proven diagnosis of Stage I NSCLC [American Joint Committee on Cancer (AJCC), 7th ed.], T1N0M0; note: T1N0 disease must be confirmed by FDG-PET/CT. (FDG = 18F-fluorodeoxyglucose; PET = positron emission tomography; CT = Computed Tomography)
- •Biopsy confirmation of diagnosis is strongly recommended but not required. If the biopsy is attempted and non-diagnostic, if the patient refuses biopsy, or if the risk of biopsy is considered too high, patients may be enrolled if the mass is suspicious for NSCLC based on 2 or more of the following criteria:
- •Positive smoking history;
- •Absence of benign calcifications within suspicious nodule;
- •Activity on PET greater than normal tissue;
- •Evidence of growth compared to previous imaging;
- •Presence of spiculation.
- •The following primary cancer types are eligible: squamous cell carcinoma; adenocarcinoma; large cell carcinoma/ large cell neuroendocrine carcinoma; non-small cell carcinoma not otherwise specified.
- •Patients with hilar or mediastinal lymph nodes ≤ 1 cm and no abnormal hilar or mediastinal uptake on PET and CT will be considered N
- •Mediastinal lymph node biopsy is required for patients with visible nodes: patients with > 1 cm hilar or mediastinal lymph nodes on CT or with nodes appearing as abnormal on PET (including suspicious but nondiagnostic uptake). Such patients will not be eligible unless directed biopsies of all abnormal lymph nodes are negative for cancer or these nodes demonstrate a lack of change during the prior 6 months and thus are considered to be non-malignant.
- •The patient must be considered a reasonable candidate for surgical resection using a lobectomy or pneumonectomy of the primary tumor within 6 weeks prior to registration, according to the following criteria based on the American College of Chest Physicians guidelines [165]:
- •A qualified thoracic surgeon should make the determination that there would be a high likelihood of negative surgical margins;
- •Baseline forced expiratory volume in 1 second (FEV1) >60% predicted, postoperative predicted FEV1 >40% predicted;
- •Diffusion capacity of the lung for carbon monoxide (DLCO) >60% predicted, postoperative predicted DLCO > 40 % predicted;
- •No baseline hypoxemia and/or hypercapnia;
- •If the estimated postoperative FEV1 or DLCO <40% predicted indicates an increased risk for perioperative complications, including death, from a standard lung cancer resection (lobectomy or greater removal of lung tissue), then cardiopulmonary exercise testing to measure maximal oxygen consumption (VO2max) must be >60%;
- •No severe pulmonary hypertension;
- •No severe cerebral, acute or chronic cardiac, or peripheral vascular disease;
- •Pleural effusion, if present, must be deemed too small to tap under CT guidance and must not be evident on chest x-ray. Pleural effusion that appears on chest x-ray will be permitted only if there is no evidence of malignancy after invasive cytologic assessment.
- •Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:
- •History/physical examination, including documentation of weight within 6 weeks prior to registration;
- •Evaluation by an experienced thoracic surgeon within 6 weeks prior to registration;
- •FDG-PET/CT scan for staging and RT plan within 4 weeks prior to registration;
- •CT scan (preferably with intravenous contrast, unless medically contraindicated) within 4 weeks prior to registration to include the entirety of both lungs, the mediastinum, liver, and adrenal glands; primary tumor dimension will be measured on CT scan.
- •Zubrod Performance Status 0-1 within 6 weeks prior to registration;
- •Age ≥ 18;
- •For women of childbearing potential, a serum or urine pregnancy test must be negative within 72 hours prior to registration;
- •Women of childbearing potential and male participants who are sexually active must practice adequate contraception during treatment if assigned to treatment with SBRT.
- •Patients must provide study specific informed consent prior to study entry.
排除标准
- •Direct evidence of regional or distant metastases after PET and surgical staging studies, or synchronous primary malignancy or prior invasive malignancy in the past 3 years, with the following exceptions:
- •carcinoma in situ;
- •early stage skin cancer that has been definitively treated;
- •when an invasive malignancy has been treated definitively and the patient has remained disease free for ≥ 3 years;
- •Primary tumors >3 cm;
- •Prior systemic chemotherapy or thoracic surgery involving lobectomy or pneumonectomy;
- •Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields;
- •Pure bronchioloalveolar carcinoma subtype of non-small cell lung cancer;
- •Active systemic, pulmonary, or pleural pericardial infection;
- •Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
结局指标
主要结局
Percentage of Participants Alive Without Local-regional Failure at Two Years (Local-regional Tumor Control)
时间窗: From date of randomization to two years
Local-regional failure (LRF) is defined differently for each arm. LRF after RODS is defined as recurrence, defined by CT, confirmed by PET/CT whenever possible, i.e., development of tumor masses at site of resection, hilum (N1 nodal region), mediastinum (N2-N3 nodes), ipsilateral supraclavicular fossa for upper lobe tumors (N3 nodes), or within 3 cm of the staple line of RODS. LRF after SBRT is defined as tumor progression on CT per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, confirmed by positron PET/CT, within same lobe, hilum (N1 nodes), mediastinum (N2-N3 nodes), or ipsilateral supraclavicular fossa for upper lobe tumors (N3 nodes), or within 3 cm of original planning target volume (PTV). Local-regional control time is defined as time from randomization to the date of first LRF, death, or last known follow-up (censored), whichever occurred first. Rates are estimated using the Kaplan-Meier method.
次要结局
- Overall Survival (Percentage of Participants Alive)(From date of randomization to date of death or last follow-up. Maximum follow-up was 7.0 years.)
- Percentage of Participants With Local-regional Failure (LRF)(From date of randomization to the date of first local-regional failure, death, or last known follow-up, whichever occurred first. Maximum follow-up is 7.0 years.)
- Percentage of Participants With Distant Failure(From date of randomization to date of first distant failure, death, or last known follow-up, whichever occurred first. Maximum follow-up was 7.0 years.)
- Percentage of Participants Alive Without Disease [Disease-free Survival (DFS)](From date of randomization to the date of first failure, death, or last known follow-up, whichever occurred first. Maximum follow-up is 7.0 years.)
- Number of Participants by Failure Site(From date of randomization to date of last known follow-up. Maximum follow-up was 7.0 years.)
- Best PET Tumor Response(From date of randomization to date of last known follow-up. Maximum follow-up was 7.0 years.)
- Number of Participants by Highest Grade Adverse Event Reported(From date of randomization to the date of last known follow-up. Maximum follow-up time was 7.0 years.)
- Number of Participants With Surgical and Radiation Treatment Credentialing Completed and Documented Before Enrollment (Trial Feasibility)(baseline)
- Number of Eligible Participants (Trial Feasibility)(Baseline)
- Number of Participants With Baseline Forms Completed and Provided Within 30 Days of Randomization (Trial Feasibility)(Baseline)
- Number of Participants Lost to Follow-up (Trial Feasibility)(From date of randomization to date of last known follow-up. Maximum follow-up was 7.0 years.)
研究者
研究点 (7)
Loading locations...
相似试验
进行中（未招募）
不适用
A PHASE II TRIAL ON NON-SMALL-CELL LUNG CANCER STEM CELLS SENSITIVITY ASSAY (LUCAS)Histologically/cytologically confirmed diagnosis of metastatic NSCLC.Possibility to obtain tumor tissue form primary tumor or from an accessible metastatic site, or possibility to collect any neoplastic effusion.Performance status of 0-1 according to ECOG score.EUCTR2012-001440-22-IT
招募中
不适用
Veterans Affairs Lung Cancer Surgery Or Stereotactic RadiotherapyLung NeoplasmNCT02984761VA Office of Research and Development670
暂停
1 期
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung CancerNon-Small Cell Lung CarcinomaCarcinoma, Non-Small-Cell LungCarcinomasNon-Small Cell Lung CancerNCT05642195National Cancer Institute (NCI)30
招募中
2 期
Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid BiopsyNon Small Cell Lung CancerNCT05469022Konkuk University Medical Center40
Unknown
2 期
To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung CancerNon-small Cell Lung Cancer Stage IIIARadiotherapyNCT02977169Shanghai Chest Hospital300